RIFAMPICIN

Brand name:

• Rimycin 150®; Rimycin 300®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• For the treatment of mycobacterium ulcerans infections (Buruli ulcer)

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

Change to listing (Minor)

Comment:

--

Submission sponsor:

Mylan

Other PBAC consideration:

--

Submission received for:

July 2020 PBAC meeting

Opportunity for consumer comment:

Open 29/04/2020 and close 10/06/2020 (see PBS Website)

PBAC meeting:

Held on 08/07/2020

PBAC outcome published:

Deferred (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---